Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.26 by 57.69 percent. This is a 278.26 percent increase over losses of $(0.23) per share from the same period last year. The company reported quarterly sales of $25.377 million which beat the analyst consensus estimate of $18.876 million by 34.44 percent. This is a 1.41K percent increase over sales of $1.677 million the same period last year.
Fennec Pharmaceuticals Q1 2024 GAAP EPS $0.41 Beats $0.26 Estimate, Sales $25.377M Beat $18.876M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.